HOME ·

ASCENTAGE

ASCENTAGE (06855.HK): Four Assets Chosen for ASH 2026, APG-5918 Oral
Tags：
ASCENTAGE06855.HKR&D Progress
2026-11-05
ASCENTAGE (06855.HK): Lisaftoclax wins breakthrough status in CLL/SLL
Tags：
ASCENTAGE06855.HKR&D Progress
2026-10-21
HANSOH's ADC Licensing Deal with Roche Worth up to USD 15 Billion and a Record Share of Chinese Studies at ESMO LBA; CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.09% Against the Trend on 20 October
Tags：
GENSCRIPT BIOASCENTAGEWUXI BIOHANSOH PHARMACSOP Hang Seng Biotech ETF
2026-10-20
ASCENTAGE (06855.HK): Interim Revenue Up 29.3% to RMB 302.2 Million, Net Loss Widens to RMB 817.0 Million
Tags：
NewTimeSpaceASCENTAGE06855.HK
2026-09-17
ASCENTAGE(06855.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 816.69 million, loss widened by 38.24% YoY
Tags：
ASCENTAGE06855.HKLoss widens
2026-08-20
Ascentage Pharma (06855.HK): Appoints Dr. Faïçal Miyara as CBO and Jim Ziegler as CCO to Strengthen Global Commercialization
Tags：
ASCENTAGE06855.HK
2026-08-03